Trials / Completed
CompletedNCT05699408
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial Comparing the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 513 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INS068 injection | INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial |
| DRUG | Insulin Glargine | Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial |
Timeline
- Start date
- 2023-03-31
- Primary completion
- 2024-11-23
- Completion
- 2024-11-23
- First posted
- 2023-01-26
- Last updated
- 2025-02-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05699408. Inclusion in this directory is not an endorsement.